Armando Lira Pineda

Statistics

Publications

Citations

4.2K

H-Index

Active since

2017

Affiliations

Thrombolysis in Myocardial Infarction Study Group(Current)

Amgen (United States)

Brigham and Women's Hospital

Imperial College London

National Health and Medical Research Council

Armando Lira Pineda is an author at Thrombolysis in Myocardial Infarction Study Group specializing in pharmacology, cardiovascular disease, and clinical pharmacology.

ORCID

Publications per year

2017–2024

Publications

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano et al. · Circulation · 2019 · 948 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Marc P. Bonaca, Patrice Nault, Robert P. Giugliano et al. · Circulation · 2017 · 754 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 677 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott et al. · The Lancet Diabetes & Endocrinology · 2017 · 596 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Inflammatory and Cholesterol Risk in the FOURIER Trial

Erin A. Bohula, Robert P. Giugliano, Lawrence A. Leiter et al. · Circulation · 2018 · 273 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 16